Biose   Report issue

For profit Phase 2 Phase 3
Founded: Aurillac France (1951)

Organization Overview

First Clinical Trial
2010
NCT01160796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Laboratoires Lyocentre

Active Ingredients

Drugs in Phase 3 Trials (1)

lactobacillus casei (1 trial)

Drugs in Phase 2 Trials (1)

lactobacillus rhamnosus (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 2)

Diarrhea (Phase 2)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2